Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

BACKGROUND: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinas, E., Luburich-Hernaiz, P., Dorca, J., Montes-Worboys, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922028/
https://www.ncbi.nlm.nih.gov/pubmed/29703175
http://dx.doi.org/10.1186/s12890-018-0626-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922028/
https://www.ncbi.nlm.nih.gov/pubmed/29703175
http://dx.doi.org/10.1186/s12890-018-0626-4

Ejemplares similares